RYTM - Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023 | Benzinga
-- More than 50 poster presentations highlighting new scientific developments to advance the care of people living with rare MC4R pathway diseases --
-- Approximately 150 healthcare professionals from 20 countries expected to attend --
BOSTON, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, is pleased to be a sponsor of the second annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) that is being held in Paris, France from December 13-15.
IMPROVE 2023 is a unique scientific meeting sponsored by Rhythm for healthcare professionals based in Europe and around the world. It is one of the few events globally that focuses solely on rare MC4R pathway diseases. This year, approximately 150 healthcare professionals will attend in person. Attendees are invited to discuss and share the latest scientific developments and patient care practices, including those driven by impairments in the MC4R pathway, in which genetic deficiencies or injury can result in hyperphagia (insatiable hunger) and early, rapid-onset severe obesity.
"As we continue to learn more about MC4R pathway-related diseases and the hyperphagia and severe obesity that present with these ...